Drugs targeting intracellular molecule: JAK inhibitor and syk inhibitor

Kunihiro Yamaoka, Kazuyoshi Saito, Yoshiya Tanaka

研究成果: Review article査読

抄録

Biologies targeting TNF-a and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologies on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologies. Here we overview the development process of these inhibitors together with the results of clinical trials.

本文言語English
ページ(範囲)23-27
ページ数5
ジャーナルJapanese Journal of Clinical Pharmacology and Therapeutics
44
1
DOI
出版ステータスPublished - 2013 1 1

ASJC Scopus subject areas

  • 薬理学
  • 薬理学(医学)

フィンガープリント

「Drugs targeting intracellular molecule: JAK inhibitor and syk inhibitor」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル